Glaxo Raises Full Year Forecast on Shingles Vaccine Demand
This article is for subscribers only.
GlaxoSmithKline Plc, the U.K.’s largest drugmaker, raised its projection for 2018 profit growth on expectations for brisk sales of its new shingles vaccine.
Adjusted earnings per share will increase 7 percent to 10 percent this year if no generic competitor to its Advair asthma drug hits the U.S. market, Glaxo said in a statement Wednesday. The company had earlier said that earnings would accelerate as much as 7 percent this year in the absence of Advair competition.